Sign in
Active, not recruitingPhase 1

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Key facts

Who runs it
Kylonova (Xiamen) Biopharma co., LTD.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
50 people, planned
Started
12 Mar 2025
Ended
30 Aug 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Kylo-12
  • Placebo
Record updated
16 March 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Men and women aged 18 to 55 years old, inclusive
  • Body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive
  • Protocol-defined elevated serum TG level
  • Female subjects must not be able to get pregnant and male subjects must agree to adhere to contraception restrictions
  • Willing to comply with protocol required visits and assessments, and provide written informed consent

Who cannot take part

  • Received an investigational drug, vaccine or device within 3 months before dosing
  • History of alcohol abuse within 12 months before dosing
  • History of drug abuse within 3 months before screening
  • History of blood donations or blood loss of 400 ml and more within 3 months before dosing
  • History of stroke or myocardial infarction within 6 months before sceening
  • History or evidence of a clinically significant disorder, condition or disease
  • History of evidence of malignant tumor or Gilbert syndrome
  • Positive screen of Hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection
  • Pregnant or breast-feeding women
  • Other exclusion criteria applied per protocol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

The 2 groups in the trial

  • Kylo-12Treatment being tested

    Single ascending doses of Kylo-12 administered subcutaneously (SC).

  • PlaceboPlacebo, for comparison

    Administered SC.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
Record updated
16 March 2026